Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double blind, placebo-controlled, parallel, international multicenter study assessing the efficacy of S066913 in patients with paroxysmal atrial fibrillation

Next Previous
Trial Profile

A randomized, double blind, placebo-controlled, parallel, international multicenter study assessing the efficacy of S066913 in patients with paroxysmal atrial fibrillation

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XEN D0103 (Primary)
  • Indications Paroxysmal atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms DIAGRAF-IKur
  • Sponsors Servier

Most Recent Events

  • 22 Sep 2016 This trial has been completed in Netherlands (End date:2016-09-06) as per European Clinical Trials Database record.
  • 02 Mar 2016 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
  • 31 Jan 2015 Status changed from planning to recruiting according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top